Effect of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions on Residual Renal Function, Urine Volume, and Ultrafiltration: A Systematic Review and Meta-Analysis

Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1380-8. doi: 10.2215/CJN.05410514. Epub 2015 Jun 5.

Abstract

Background and objectives: Neutral-pH, low-glucose degradation products solutions were developed in an attempt to lessen the adverse effects of conventional peritoneal dialysis solutions. A systematic review was performed evaluating the effect of these solutions on residual renal function, urine volume, peritoneal ultrafiltration, and peritoneal small-solute transport (dialysate to plasma creatinine ratio) over time.

Design, setting, participants, & measurements: Multiple electronic databases were searched from January of 1995 to January of 2013. Randomized trials reporting on any of four prespecified outcomes were selected by consensus among multiple reviewers.

Results: Eleven trials of 643 patients were included. Trials were generally of poor quality. The meta-analysis was performed using a random effects model. The use of neutral-pH, low-glucose degradation products solutions resulted in better preserved residual renal function at various study durations, including >1 year (combined analysis: 11 studies; 643 patients; standardized mean difference =0.17 ml/min; 95% confidence interval, 0.01 to 0.32), and greater urine volumes (eight studies; 598 patients; mean difference =128 ml/d; 95% confidence interval, 58 to 198). There was no significant difference in peritoneal ultrafiltration (seven studies; 571 patients; mean difference =-110; 95% confidence interval, -312 to 91) or dialysate to plasma creatinine ratio (six studies; 432 patients; mean difference =0.03; 95% confidence interval, 0.00 to 0.06).

Conclusions: The use of neutral-pH, low-glucose degradation products solutions results in better preservation of residual renal function and greater urine volumes. The effect on residual renal function occurred early and persisted beyond 12 months. Additional studies are required to evaluate the use of neutral-pH, low-glucose degradation products solutions on hard clinical outcomes.

Keywords: biocompatible; degradation products; glucose; peritoneal dialysis; residual renal function; urine volume.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Biomarkers / blood
  • Chi-Square Distribution
  • Creatinine / blood
  • Dialysis Solutions / adverse effects
  • Dialysis Solutions / chemistry
  • Dialysis Solutions / metabolism
  • Dialysis Solutions / therapeutic use*
  • Glucose / chemistry*
  • Humans
  • Hydrogen-Ion Concentration
  • Kidney / physiopathology*
  • Kidney Diseases / blood
  • Kidney Diseases / diagnosis
  • Kidney Diseases / physiopathology
  • Kidney Diseases / therapy*
  • Peritoneal Dialysis / adverse effects
  • Peritoneal Dialysis / methods*
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Treatment Outcome
  • Urination
  • Urodynamics

Substances

  • Biomarkers
  • Dialysis Solutions
  • Creatinine
  • Glucose